Neoplasms

All Conditions

Rare Diseases

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Germ Cells Tumors

Antineoplastic Agents

All Drugs and Chemicals

Bevacizumab

Carboplatin

Etoposide

Ifosfamide

Lenograstim

Etoposide phosphate

Isophosphamide mustard

Antineoplastic Agents, Immunological

Angiogenesis Inhibitors

Growth Inhibitors

Two intensified treatments at 6-week intervals will start on D69 (max D76) and D111 (max J118) respectively, combining:

* A bevacizumab treatment: 7.5 mg/kg every 3 weeks from D1 to the first intensified treatment for a total of 4 injections.
* The ICE chemotherapy regimen:

  1. Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals,
  2. Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance,
  3. Ifosfamide, 2400 mg/m²/d,
  4. For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle

Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle

ICE chemotherapy regimen

Frédéric SELLE, MD

High-dose chemotherapy with autologous hematopoietic stem-cell transplantation is a standard salvage treatment used in adults with germ cell tumors (Einhorn et al, J Clin Oncol 2007).

Disease prognosis following 1 to 2 intensified combinations of etoposide - carboplatin +/- ifosfamide depends on the patient's performance status (PS) at inclusion and the prior sensitivity of the disease to cisplatin. A poor PS and/or being refractory to cisplatin suggest a higher toxicity and a bad prognosis.

However, predictive factors of response to high-dose chemotherapy do not include a chemo-sensitivity phase with a semi-intensive chemotherapy excluding a platinum compound (epirubicin - paclitaxel), which still allows stem-cell harvest. The use of this chemotherapy combination induced a response in more than one third of the patients treated during disease progression in the TAXIF I study. The same strategy was tested in the TAXIF II study, which completed the inclusion of 45 patients and was closed in May 2008. Results of the TAXIF II study, are currently being analyzed; they support the hypothesis to prioritarily treat patients with a sensitive relapsed disease at the time of the high-dose administration.

A combination of a semi-intensive sequential ICE type chemotherapy plus bevacizumab was used on a highly refractory patient. A 5 months nearly complete response was achieved. Indeed, the overexpression of VEGF (Vascular Endothelial Growth Factor) has been identified as an independent risk factor in patients with germ cell tumor. Therefore, a treatment strategy using an inductive chemotherapy followed, in case of response, by a double intensification therapy in combination with a VEGF treatment, could be an interesting approach in patients with poor prognosis germ cell tumors.

The aim of this phase I/II trial is to assess the feasibility of a Bevacizumab - ICE (Ifosfamide-Carboplatin-Etoposide) high dose combination with the support of autologous hematopoietic stem cell for two intensive consecutive cycles ("tandem" intensification) in patients with a poor prognosis germ cell tumor non refractory to a front-line mobilization chemotherapy using two half intensified consecutive combinations of Epirubicin-Paclitaxel.

Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors

Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors - A Phase I-II Sequential Chemotherapy Protocol of Bevacizumab (Avastin) Plus High-dose ICE (Ifosfamide - Carboplatin - Etoposide) Intensification

Partial response or complete response evaluated by scanography and assay for tumor marker(s) a month after the end of the 2 cycles

Safety recorded according to CTCAE-v4 criteria

Assistance Publique - Hôpitaux de Paris

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors	NCT01966913	Germ Cell Tumor	Bevacizumab ICE chemotherap...	18 Years -	Assistance Publique - Hôpitaux de Paris
Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors	NCT01966913	Germ Cell Tumor	Bevacizumab ICE chemotherap...	18 Years -	Assistance Publique - Hôpitaux de Paris

Spots Global Cancer Trial Database for ice chemotherapy regimen